The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

NEW YORK – Elicio Therapeutics is planning a pivotal trial of its KRAS-targeting cancer vaccine ELI-002, hoping to show that it can delay or prevent the return of RAS-mutant pancreatic and colorectal ...

NEW YORK – ALX Oncology is transitioning from a broad immuno-oncology strategy to a personalized medicine approach for at least two of its therapeutic programs: the EGFR-targeted antibody-drug ...

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...